Molecular Basis of Lipoprotein Disorders, Atherogenesis, and Thrombosis

Marı́n-Garcı́a, José; Goldenthal, Michael J.; Moe, Gordon W.

doi:10.1016/b978-012373698-7/50008-5

Cited by 2 publications

(1 citation statement)

References 425 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This cleavage exposes binding sites on fibrinogen, allowing individual fibrinogen molecules to join and produce fibrin monomers. The subsequent polymerization of these monomers, assisted by factor XIIIa, results in the formation of a network of lengthy fibrin strands [79]. The fibrin network serves as the structure that supports a blood clot.…”

Section: C) Fibrinogen Alpha Chainmentioning

confidence: 99%

The correlation of gene mutation of coagulopathy cascade with elevated D-dimer levels in COVID-19 patients

Albalbaki,

AL-Fawares,

Aburayyan

et al. 2023

J Appl Pharm Sci

View full text Add to dashboard Cite

SARS-CoV-2 had a pertinent implication on people's daily lives and medical procedures during the pandemic or even after it. COVID-19 infections varied in the clinical aspect from mortality to asymptomatic episodes. The symptoms included fever, cough, difficulty breathing, loss of mobility, and chest pain. On the other hand, the patients who passed away from COVID-19 showed multiple organ failure, respiratory dysfunction, and disseminated coagulations throughout the body. D-dimer is a biomarker implemented in blood clotting and is commonly elevated in patients with thrombotic complications. This review sheds light on the correlation between gene mutations in the coagulopathy cascade among COVID-19 patients with high D-dimer levels. The elevated D-dimer levels are significantly associated with mutations in genes involved in the coagulopathy cascade. The findings suggest that these mutations may play an important role in developing thrombotic problems in COVID-19 patients. As a result, understanding the genetic basis of thrombotic development in COVID-19 could lead to new ways of avoiding and treating thrombotic problems.

show abstract

Section: C) Fibrinogen Alpha Chainmentioning

confidence: 99%

The correlation of gene mutation of coagulopathy cascade with elevated D-dimer levels in COVID-19 patients

Albalbaki,

AL-Fawares,

Aburayyan

et al. 2023

J Appl Pharm Sci

View full text Add to dashboard Cite

show abstract

“iPSC-derived liver organoids and inherited bleeding disorders: Potential and future perspectives”

Roman

Stavik²,

Lauritzen³

et al. 2023

Front. Physiol.

View full text Add to dashboard Cite

The bleeding phenotype of hereditary coagulation disorders is caused by the low or undetectable activity of the proteins involved in hemostasis, due to a broad spectrum of genetic alterations. Most of the affected coagulation factors are produced in the liver. Therefore, two-dimensional (2D) cultures of primary human hepatocytes and recombinant overexpression of the factors in non-human cell lines have been primarily used to mimic disease pathogenesis and as a model for innovative therapeutic strategies. However, neither human nor animal cells fully represent the hepatocellular biology and do not harbor the exact genetic background of the patient. As a result, the inability of the current in vitro models in recapitulating the in vivo situation has limited the studies of these inherited coagulation disorders. Induced Pluripotent Stem Cell (iPSC) technology offers a possible solution to overcome these limitations by reprogramming patient somatic cells into an embryonic-like pluripotent state, thus giving the possibility of generating an unlimited number of liver cells needed for modeling or therapeutic purposes. By combining this potential and the recent advances in the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 technology, it allows for the generation of autologous and gene corrected liver cells in the form of three-dimensional (3D) liver organoids. The organoids recapitulate cellular composition and organization of the liver, providing a more physiological model to study the biology of coagulation proteins and modeling hereditary coagulation disorders. This advanced methodology can pave the way for the development of cell-based therapeutic approaches to treat inherited coagulation disorders. In this review we will explore the use of liver organoids as a state-of-the-art methodology for modeling coagulation factors disorders and the possibilities of using organoid technology to treat the disease.

show abstract

Molecular Basis of Lipoprotein Disorders, Atherogenesis, and Thrombosis

Cited by 2 publications

References 425 publications

The correlation of gene mutation of coagulopathy cascade with elevated D-dimer levels in COVID-19 patients

The correlation of gene mutation of coagulopathy cascade with elevated D-dimer levels in COVID-19 patients

“iPSC-derived liver organoids and inherited bleeding disorders: Potential and future perspectives”

Contact Info

Product

Resources

About